| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | granulocyte colony-stimulating factor receptor binding | 4.37e-06 | 14 | 47 | 3 | GO:0005130 | |
| GeneOntologyMolecularFunction | glycolipid binding | 5.28e-06 | 49 | 47 | 4 | GO:0051861 | |
| GeneOntologyMolecularFunction | lipid transporter activity | 6.36e-06 | 196 | 47 | 6 | GO:0005319 | |
| GeneOntologyMolecularFunction | GPI anchor binding | 2.09e-05 | 23 | 47 | 3 | GO:0034235 | |
| GeneOntologyMolecularFunction | lipid transmembrane transporter activity | 2.60e-05 | 73 | 47 | 4 | GO:0170055 | |
| GeneOntologyMolecularFunction | filamin binding | 4.28e-05 | 29 | 47 | 3 | GO:0031005 | |
| GeneOntologyMolecularFunction | Toll-like receptor binding | 4.28e-05 | 29 | 47 | 3 | GO:0035325 | |
| GeneOntologyMolecularFunction | monocarboxylic acid transmembrane transporter activity | 5.93e-05 | 90 | 47 | 4 | GO:0008028 | |
| GeneOntologyMolecularFunction | bile acid transmembrane transporter activity | 6.95e-05 | 34 | 47 | 3 | GO:0015125 | |
| GeneOntologyMolecularFunction | phosphatidylinositol binding | 9.32e-05 | 316 | 47 | 6 | GO:0035091 | |
| GeneOntologyMolecularFunction | phospholipid binding | 2.74e-04 | 548 | 47 | 7 | GO:0005543 | |
| GeneOntologyMolecularFunction | protein homodimerization activity | 5.69e-04 | 815 | 47 | 8 | GO:0042803 | |
| GeneOntologyMolecularFunction | organic hydroxy compound transmembrane transporter activity | 5.99e-04 | 70 | 47 | 3 | GO:1901618 | |
| GeneOntologyMolecularFunction | floppase activity | 6.37e-04 | 16 | 47 | 2 | GO:0140328 | |
| GeneOntologyMolecularFunction | growth factor receptor binding | 7.26e-04 | 173 | 47 | 4 | GO:0070851 | |
| GeneOntologyMolecularFunction | actin binding | 8.62e-04 | 479 | 47 | 6 | GO:0003779 | |
| GeneOntologyMolecularFunction | ceramide binding | 1.00e-03 | 20 | 47 | 2 | GO:0097001 | |
| GeneOntologyMolecularFunction | carboxylic acid transmembrane transporter activity | 1.41e-03 | 207 | 47 | 4 | GO:0046943 | |
| GeneOntologyMolecularFunction | organic acid transmembrane transporter activity | 1.44e-03 | 208 | 47 | 4 | GO:0005342 | |
| GeneOntologyMolecularFunction | kinase binding | 1.74e-03 | 969 | 47 | 8 | GO:0019900 | |
| GeneOntologyMolecularFunction | lipid binding | 1.97e-03 | 988 | 47 | 8 | GO:0008289 | |
| GeneOntologyMolecularFunction | ATPase-coupled intramembrane lipid transporter activity | 1.97e-03 | 28 | 47 | 2 | GO:0140326 | |
| GeneOntologyMolecularFunction | calmodulin binding | 2.07e-03 | 230 | 47 | 4 | GO:0005516 | |
| GeneOntologyMolecularFunction | sphingolipid binding | 2.90e-03 | 34 | 47 | 2 | GO:0046625 | |
| GeneOntologyMolecularFunction | 3'-5'-RNA exonuclease activity | 3.43e-03 | 37 | 47 | 2 | GO:0000175 | |
| GeneOntologyMolecularFunction | RNA exonuclease activity, producing 5'-phosphomonoesters | 4.00e-03 | 40 | 47 | 2 | GO:0016896 | |
| GeneOntologyMolecularFunction | protein kinase binding | 4.07e-03 | 873 | 47 | 7 | GO:0019901 | |
| GeneOntologyMolecularFunction | organic anion transmembrane transporter activity | 4.93e-03 | 293 | 47 | 4 | GO:0008514 | |
| GeneOntologyMolecularFunction | RNA exonuclease activity | 5.03e-03 | 45 | 47 | 2 | GO:0004532 | |
| GeneOntologyMolecularFunction | protein tyrosine kinase binding | 5.19e-03 | 149 | 47 | 3 | GO:1990782 | |
| GeneOntologyMolecularFunction | amide binding | 5.30e-03 | 299 | 47 | 4 | GO:0033218 | |
| GeneOntologyMolecularFunction | ABC-type transporter activity | 5.94e-03 | 49 | 47 | 2 | GO:0140359 | |
| GeneOntologyMolecularFunction | intramembrane lipid transporter activity | 6.42e-03 | 51 | 47 | 2 | GO:0140303 | |
| GeneOntologyMolecularFunction | protein dimerization activity | 6.59e-03 | 1205 | 47 | 8 | GO:0046983 | |
| GeneOntologyMolecularFunction | cytokine receptor binding | 7.01e-03 | 324 | 47 | 4 | GO:0005126 | |
| GeneOntologyMolecularFunction | calcium channel regulator activity | 7.18e-03 | 54 | 47 | 2 | GO:0005246 | |
| GeneOntologyMolecularFunction | peptide hormone binding | 7.44e-03 | 55 | 47 | 2 | GO:0017046 | |
| GeneOntologyMolecularFunction | 3'-5' exonuclease activity | 9.08e-03 | 61 | 47 | 2 | GO:0008408 | |
| GeneOntologyMolecularFunction | exonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 5'-phosphomonoesters | 9.37e-03 | 62 | 47 | 2 | GO:0016796 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 2.03e-07 | 23 | 47 | 4 | GO:0002858 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immune response to tumor cell | 2.43e-07 | 24 | 47 | 4 | GO:0002855 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity directed against tumor cell target | 2.43e-07 | 24 | 47 | 4 | GO:0002420 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immune response to tumor cell | 2.89e-07 | 25 | 47 | 4 | GO:0002423 | |
| GeneOntologyBiologicalProcess | negative regulation of wound healing | 2.86e-06 | 98 | 47 | 5 | GO:0061045 | |
| GeneOntologyBiologicalProcess | negative regulation of brown fat cell proliferation | 3.97e-06 | 14 | 47 | 3 | GO:0070348 | |
| GeneOntologyBiologicalProcess | regulation of immune response to tumor cell | 4.65e-06 | 49 | 47 | 4 | GO:0002837 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immune response to tumor cell | 4.95e-06 | 15 | 47 | 3 | GO:0002856 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity directed against tumor cell target | 4.95e-06 | 15 | 47 | 3 | GO:0002859 | |
| GeneOntologyBiologicalProcess | regulation of brown fat cell proliferation | 4.95e-06 | 15 | 47 | 3 | GO:0070347 | |
| GeneOntologyBiologicalProcess | positive regulation of homophilic cell adhesion | 4.95e-06 | 15 | 47 | 3 | GO:1903387 | |
| GeneOntologyBiologicalProcess | regulation of response to tumor cell | 5.05e-06 | 50 | 47 | 4 | GO:0002834 | |
| GeneOntologyBiologicalProcess | insulin receptor internalization | 6.08e-06 | 16 | 47 | 3 | GO:0038016 | |
| GeneOntologyBiologicalProcess | negative regulation of cytokine production | 6.52e-06 | 444 | 47 | 8 | GO:0001818 | |
| GeneOntologyBiologicalProcess | brown fat cell proliferation | 7.37e-06 | 17 | 47 | 3 | GO:0070342 | |
| GeneOntologyBiologicalProcess | granulocyte colony-stimulating factor signaling pathway | 7.37e-06 | 17 | 47 | 3 | GO:0038158 | |
| GeneOntologyBiologicalProcess | insulin catabolic process | 7.37e-06 | 17 | 47 | 3 | GO:1901143 | |
| GeneOntologyBiologicalProcess | immune response to tumor cell | 7.97e-06 | 56 | 47 | 4 | GO:0002418 | |
| GeneOntologyBiologicalProcess | regulation of homophilic cell adhesion | 8.83e-06 | 18 | 47 | 3 | GO:1903385 | |
| GeneOntologyBiologicalProcess | negative regulation of response to wounding | 9.81e-06 | 126 | 47 | 5 | GO:1903035 | |
| GeneOntologyBiologicalProcess | negative regulation of hepatocyte proliferation | 1.23e-05 | 20 | 47 | 3 | GO:2000346 | |
| GeneOntologyBiologicalProcess | negative regulation of response to tumor cell | 1.43e-05 | 21 | 47 | 3 | GO:0002835 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response to tumor cell | 1.43e-05 | 21 | 47 | 3 | GO:0002838 | |
| GeneOntologyBiologicalProcess | negative regulation of fat cell proliferation | 1.43e-05 | 21 | 47 | 3 | GO:0070345 | |
| GeneOntologyBiologicalProcess | negative regulation of granulocyte differentiation | 1.66e-05 | 22 | 47 | 3 | GO:0030853 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet aggregation | 1.90e-05 | 23 | 47 | 3 | GO:0090331 | |
| GeneOntologyBiologicalProcess | regulation of bone resorption | 1.94e-05 | 70 | 47 | 4 | GO:0045124 | |
| GeneOntologyBiologicalProcess | regulation of vascular permeability | 2.06e-05 | 71 | 47 | 4 | GO:0043114 | |
| GeneOntologyBiologicalProcess | response to tumor cell | 2.06e-05 | 71 | 47 | 4 | GO:0002347 | |
| GeneOntologyBiologicalProcess | positive regulation of vasculogenesis | 2.17e-05 | 24 | 47 | 3 | GO:2001214 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid biosynthetic process | 2.30e-05 | 73 | 47 | 4 | GO:0042304 | |
| GeneOntologyBiologicalProcess | common myeloid progenitor cell proliferation | 2.46e-05 | 25 | 47 | 3 | GO:0035726 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 2.69e-05 | 76 | 47 | 4 | GO:0042269 | |
| GeneOntologyBiologicalProcess | regulation of fat cell proliferation | 3.12e-05 | 27 | 47 | 3 | GO:0070344 | |
| GeneOntologyBiologicalProcess | regulation of bone remodeling | 3.30e-05 | 80 | 47 | 4 | GO:0046850 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 3.30e-05 | 80 | 47 | 4 | GO:0002715 | |
| GeneOntologyBiologicalProcess | negative regulation of homotypic cell-cell adhesion | 3.49e-05 | 28 | 47 | 3 | GO:0034111 | |
| GeneOntologyBiologicalProcess | regulation of wound healing | 3.71e-05 | 166 | 47 | 5 | GO:0061041 | |
| GeneOntologyBiologicalProcess | regulation of vasculogenesis | 3.89e-05 | 29 | 47 | 3 | GO:2001212 | |
| GeneOntologyBiologicalProcess | regulation of epidermal growth factor receptor signaling pathway | 4.38e-05 | 86 | 47 | 4 | GO:0042058 | |
| GeneOntologyBiologicalProcess | negative regulation of platelet activation | 4.77e-05 | 31 | 47 | 3 | GO:0010544 | |
| GeneOntologyBiologicalProcess | regulation of blood vessel remodeling | 5.25e-05 | 32 | 47 | 3 | GO:0060312 | |
| GeneOntologyBiologicalProcess | negative regulation of bone resorption | 5.25e-05 | 32 | 47 | 3 | GO:0045779 | |
| GeneOntologyBiologicalProcess | fat cell proliferation | 5.25e-05 | 32 | 47 | 3 | GO:0070341 | |
| GeneOntologyBiologicalProcess | negative regulation of lipid biosynthetic process | 5.47e-05 | 91 | 47 | 4 | GO:0051055 | |
| GeneOntologyBiologicalProcess | negative regulation of feeding behavior | 5.77e-05 | 33 | 47 | 3 | GO:2000252 | |
| GeneOntologyBiologicalProcess | regulation of granulocyte differentiation | 5.77e-05 | 33 | 47 | 3 | GO:0030852 | |
| GeneOntologyBiologicalProcess | regulation of ERBB signaling pathway | 5.96e-05 | 93 | 47 | 4 | GO:1901184 | |
| GeneOntologyBiologicalProcess | negative regulation of vascular permeability | 6.31e-05 | 34 | 47 | 3 | GO:0043116 | |
| GeneOntologyBiologicalProcess | negative regulation of bone remodeling | 6.31e-05 | 34 | 47 | 3 | GO:0046851 | |
| GeneOntologyBiologicalProcess | insulin metabolic process | 6.90e-05 | 35 | 47 | 3 | GO:1901142 | |
| GeneOntologyBiologicalProcess | regulation of cytokine production | 7.50e-05 | 1010 | 47 | 10 | GO:0001817 | |
| GeneOntologyBiologicalProcess | bone resorption | 7.60e-05 | 99 | 47 | 4 | GO:0045453 | |
| GeneOntologyBiologicalProcess | regulation of hepatocyte proliferation | 8.85e-05 | 38 | 47 | 3 | GO:2000345 | |
| GeneOntologyBiologicalProcess | negative regulation of multicellular organismal process | MAG NPR1 PSG3 PSG4 PSG9 LAPTM4B CRTAM NAV3 MUC16 LTBP3 ABCD1 PRG4 | 9.26e-05 | 1488 | 47 | 12 | GO:0051241 |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity | 9.56e-05 | 105 | 47 | 4 | GO:0042267 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid biosynthetic process | 9.57e-05 | 39 | 47 | 3 | GO:0045717 | |
| GeneOntologyBiologicalProcess | negative regulation of T cell proliferation | 1.03e-04 | 107 | 47 | 4 | GO:0042130 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 1.03e-04 | 40 | 47 | 3 | GO:0045953 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immunity | 1.10e-04 | 109 | 47 | 4 | GO:0002228 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 1.11e-04 | 41 | 47 | 3 | GO:0002716 | |
| GeneOntologyBiologicalProcess | regulation of platelet aggregation | 1.20e-04 | 42 | 47 | 3 | GO:0090330 | |
| GeneOntologyBiologicalProcess | vascular process in circulatory system | 1.24e-04 | 344 | 47 | 6 | GO:0003018 | |
| GeneOntologyBiologicalProcess | regulation of response to wounding | 1.32e-04 | 217 | 47 | 5 | GO:1903034 | |
| GeneOntologyBiologicalProcess | cytokine production | 1.42e-04 | 1091 | 47 | 10 | GO:0001816 | |
| GeneOntologyBiologicalProcess | negative regulation of behavior | 1.47e-04 | 45 | 47 | 3 | GO:0048521 | |
| GeneOntologyBiologicalProcess | epithelial cell proliferation involved in liver morphogenesis | 1.57e-04 | 46 | 47 | 3 | GO:0072575 | |
| GeneOntologyBiologicalProcess | hepatocyte proliferation | 1.57e-04 | 46 | 47 | 3 | GO:0072574 | |
| GeneOntologyBiologicalProcess | bile acid and bile salt transport | 1.68e-04 | 47 | 47 | 3 | GO:0015721 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 1.68e-04 | 47 | 47 | 3 | GO:0001911 | |
| GeneOntologyBiologicalProcess | negative regulation of tissue remodeling | 1.68e-04 | 47 | 47 | 3 | GO:0034104 | |
| GeneOntologyBiologicalProcess | central nervous system myelin formation | 1.81e-04 | 9 | 47 | 2 | GO:0032289 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte proliferation | 1.82e-04 | 124 | 47 | 4 | GO:0050672 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte mediated cytotoxicity | 1.82e-04 | 124 | 47 | 4 | GO:0001910 | |
| GeneOntologyBiologicalProcess | liver morphogenesis | 1.90e-04 | 49 | 47 | 3 | GO:0072576 | |
| GeneOntologyBiologicalProcess | negative regulation of mononuclear cell proliferation | 1.93e-04 | 126 | 47 | 4 | GO:0032945 | |
| GeneOntologyBiologicalProcess | regulation of T cell proliferation | 1.95e-04 | 236 | 47 | 5 | GO:0042129 | |
| GeneOntologyBiologicalProcess | bone remodeling | 1.99e-04 | 127 | 47 | 4 | GO:0046849 | |
| GeneOntologyBiologicalProcess | regulation of tissue remodeling | 2.05e-04 | 128 | 47 | 4 | GO:0034103 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 2.27e-04 | 52 | 47 | 3 | GO:0031342 | |
| GeneOntologyBiologicalProcess | regulation of lipid biosynthetic process | 2.36e-04 | 246 | 47 | 5 | GO:0046890 | |
| GeneOntologyBiologicalProcess | regulation of homotypic cell-cell adhesion | 2.40e-04 | 53 | 47 | 3 | GO:0034110 | |
| GeneOntologyBiologicalProcess | regulation of fatty acid metabolic process | 2.45e-04 | 134 | 47 | 4 | GO:0019217 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte proliferation | 2.45e-04 | 134 | 47 | 4 | GO:0070664 | |
| GeneOntologyBiologicalProcess | epidermal growth factor receptor signaling pathway | 2.81e-04 | 139 | 47 | 4 | GO:0007173 | |
| GeneOntologyBiologicalProcess | negative regulation of osteoclast differentiation | 3.30e-04 | 59 | 47 | 3 | GO:0045671 | |
| GeneOntologyBiologicalProcess | negative regulation of lipid metabolic process | 3.30e-04 | 145 | 47 | 4 | GO:0045833 | |
| GeneOntologyBiologicalProcess | granulocyte differentiation | 3.46e-04 | 60 | 47 | 3 | GO:0030851 | |
| GeneOntologyBiologicalProcess | negative regulation of fatty acid metabolic process | 3.46e-04 | 60 | 47 | 3 | GO:0045922 | |
| GeneOntologyBiologicalProcess | regulation of cell killing | 3.48e-04 | 147 | 47 | 4 | GO:0031341 | |
| GeneOntologyBiologicalProcess | regulation of feeding behavior | 3.64e-04 | 61 | 47 | 3 | GO:0060259 | |
| GeneOntologyBiologicalProcess | platelet activation | 4.58e-04 | 158 | 47 | 4 | GO:0030168 | |
| GeneOntologyBiologicalProcess | regulation of platelet activation | 4.59e-04 | 66 | 47 | 3 | GO:0010543 | |
| GeneOntologyBiologicalProcess | regulation of endothelial cell differentiation | 4.80e-04 | 67 | 47 | 3 | GO:0045601 | |
| GeneOntologyBiologicalProcess | ERBB signaling pathway | 4.80e-04 | 160 | 47 | 4 | GO:0038127 | |
| GeneOntologyBiologicalProcess | T cell proliferation | 4.87e-04 | 288 | 47 | 5 | GO:0042098 | |
| GeneOntologyBiologicalProcess | feeding behavior | 5.03e-04 | 162 | 47 | 4 | GO:0007631 | |
| GeneOntologyBiologicalProcess | negative regulation of blood coagulation | 5.23e-04 | 69 | 47 | 3 | GO:0030195 | |
| GeneOntologyBiologicalProcess | negative regulation of hemostasis | 5.45e-04 | 70 | 47 | 3 | GO:1900047 | |
| GeneOntologyBiologicalProcess | negative regulation of interleukin-1 production | 5.92e-04 | 72 | 47 | 3 | GO:0032692 | |
| GeneOntologyCellularComponent | transforming growth factor beta ligand-receptor complex | 5.12e-06 | 16 | 45 | 3 | GO:0070021 | |
| GeneOntologyCellularComponent | lysosomal membrane | 4.43e-04 | 462 | 45 | 6 | GO:0005765 | |
| GeneOntologyCellularComponent | lytic vacuole membrane | 4.43e-04 | 462 | 45 | 6 | GO:0098852 | |
| GeneOntologyCellularComponent | side of membrane | 4.96e-04 | 875 | 45 | 8 | GO:0098552 | |
| GeneOntologyCellularComponent | apical plasma membrane | 5.84e-04 | 487 | 45 | 6 | GO:0016324 | |
| GeneOntologyCellularComponent | vacuolar membrane | 7.21e-04 | 507 | 45 | 6 | GO:0005774 | |
| GeneOntologyCellularComponent | lateral plasma membrane | 9.61e-04 | 90 | 45 | 3 | GO:0016328 | |
| GeneOntologyCellularComponent | adherens junction | 1.11e-03 | 212 | 45 | 4 | GO:0005912 | |
| GeneOntologyCellularComponent | ciliary membrane | 1.23e-03 | 98 | 45 | 3 | GO:0060170 | |
| GeneOntologyCellularComponent | apical part of cell | 1.60e-03 | 592 | 45 | 6 | GO:0045177 | |
| MousePheno | decreased susceptibility to Coronaviridae infection induced morbidity/mortality | 1.13e-05 | 17 | 37 | 3 | MP:0031047 | |
| MousePheno | increased skeletal muscle triglyceride level | 2.20e-05 | 21 | 37 | 3 | MP:0031415 | |
| MousePheno | decreased fatty acid oxidation | 3.33e-05 | 24 | 37 | 3 | MP:0014172 | |
| MousePheno | increased abdominal fat pad weight | 4.78e-05 | 27 | 37 | 3 | MP:0009286 | |
| MousePheno | decreased susceptibility to Coronaviridae infection | 5.34e-05 | 28 | 37 | 3 | MP:0020950 | |
| MousePheno | abnormal skeletal muscle triglyceride level | 7.29e-05 | 31 | 37 | 3 | MP:0031413 | |
| MousePheno | decreased carbon dioxide production | 7.29e-05 | 31 | 37 | 3 | MP:0008964 | |
| MousePheno | decreased skeletal muscle cell glucose uptake | 1.05e-04 | 35 | 37 | 3 | MP:0031618 | |
| MousePheno | abnormal muscle triglyceride level | 1.15e-04 | 36 | 37 | 3 | MP:0031412 | |
| MousePheno | decreased muscle cell glucose uptake | 1.46e-04 | 39 | 37 | 3 | MP:0030022 | |
| MousePheno | decreased respiratory quotient | 1.96e-04 | 110 | 37 | 4 | MP:0010379 | |
| MousePheno | decreased susceptibility to Riboviria infection induced morbidity/mortality | 2.10e-04 | 44 | 37 | 3 | MP:0031023 | |
| MousePheno | abnormal skeletal muscle cell glucose uptake | 2.55e-04 | 47 | 37 | 3 | MP:0031617 | |
| MousePheno | abnormal susceptibility to Coronaviridae infection | 2.89e-04 | 49 | 37 | 3 | MP:0020948 | |
| MousePheno | tremors | 2.98e-04 | 353 | 37 | 6 | MP:0000745 | |
| MousePheno | decreased cellular glucose uptake | 3.65e-04 | 53 | 37 | 3 | MP:0003926 | |
| MousePheno | abnormal fatty acid oxidation | 3.86e-04 | 54 | 37 | 3 | MP:0010953 | |
| MousePheno | abnormal third pharyngeal arch artery morphology | 5.22e-04 | 13 | 37 | 2 | MP:0006356 | |
| MousePheno | decreased susceptibility to viral infection induced morbidity/mortality | 5.26e-04 | 60 | 37 | 3 | MP:0009790 | |
| MousePheno | abnormal lipid oxidation | 5.53e-04 | 61 | 37 | 3 | MP:0010951 | |
| MousePheno | increased insulin secretion | 6.36e-04 | 64 | 37 | 3 | MP:0003058 | |
| MousePheno | abnormal muscle cell glucose uptake | 7.28e-04 | 67 | 37 | 3 | MP:0004130 | |
| MousePheno | abnormal carbon dioxide production | 7.28e-04 | 67 | 37 | 3 | MP:0008962 | |
| MousePheno | abnormal fourth pharyngeal arch artery morphology | 9.04e-04 | 17 | 37 | 2 | MP:0006354 | |
| MousePheno | abnormal vascular wound healing | 9.35e-04 | 73 | 37 | 3 | MP:0004883 | |
| MousePheno | abnormal neurite morphology | 9.77e-04 | 442 | 37 | 6 | MP:0008415 | |
| MousePheno | abnormal third pharyngeal arch morphology | 1.13e-03 | 19 | 37 | 2 | MP:0006339 | |
| MousePheno | decreased oxygen consumption | 1.18e-03 | 79 | 37 | 3 | MP:0005290 | |
| MousePheno | abnormal respiratory quotient | 1.21e-03 | 178 | 37 | 4 | MP:0004129 | |
| MousePheno | polyphagia | 1.22e-03 | 80 | 37 | 3 | MP:0001433 | |
| MousePheno | abnormal parathyroid gland morphology | 1.26e-03 | 20 | 37 | 2 | MP:0000678 | |
| MousePheno | decreased susceptibility to Riboviria infection | 1.31e-03 | 82 | 37 | 3 | MP:0020914 | |
| Domain | V-set | 9.64e-05 | 184 | 47 | 5 | PF07686 | |
| Domain | Ig_V-set | 1.39e-04 | 199 | 47 | 5 | IPR013106 | |
| Domain | Ig_2 | 8.21e-04 | 73 | 47 | 3 | PF13895 | |
| Domain | ig | 1.32e-03 | 190 | 47 | 4 | PF00047 | |
| Domain | Immunoglobulin | 1.32e-03 | 190 | 47 | 4 | IPR013151 | |
| Domain | IGc2 | 2.85e-03 | 235 | 47 | 4 | SM00408 | |
| Domain | Ig_sub2 | 2.85e-03 | 235 | 47 | 4 | IPR003598 | |
| Domain | IG | 4.00e-03 | 421 | 47 | 5 | SM00409 | |
| Domain | Ig_sub | 4.00e-03 | 421 | 47 | 5 | IPR003599 | |
| Domain | Pkinase_Tyr | 4.18e-03 | 129 | 47 | 3 | PF07714 | |
| Domain | C2-set_2 | 4.77e-03 | 41 | 47 | 2 | PF08205 | |
| Domain | CD80_C2-set | 4.77e-03 | 41 | 47 | 2 | IPR013162 | |
| Domain | ABC_transporter_CS | 5.01e-03 | 42 | 47 | 2 | IPR017871 | |
| Domain | Ser-Thr/Tyr_kinase_cat_dom | 5.05e-03 | 138 | 47 | 3 | IPR001245 | |
| Domain | AAA+_ATPase | 5.68e-03 | 144 | 47 | 3 | IPR003593 | |
| Domain | AAA | 5.68e-03 | 144 | 47 | 3 | SM00382 | |
| Domain | - | 6.09e-03 | 663 | 47 | 6 | 2.60.40.10 | |
| Domain | ABC_TRANSPORTER_2 | 6.49e-03 | 48 | 47 | 2 | PS50893 | |
| Domain | ABC_tran | 6.49e-03 | 48 | 47 | 2 | PF00005 | |
| Domain | ABC_TRANSPORTER_1 | 6.76e-03 | 49 | 47 | 2 | PS00211 | |
| Domain | ABC_transporter-like | 7.03e-03 | 50 | 47 | 2 | IPR003439 | |
| Domain | IG_LIKE | 7.61e-03 | 491 | 47 | 5 | PS50835 | |
| Domain | Ig-like_fold | 8.20e-03 | 706 | 47 | 6 | IPR013783 | |
| Domain | Ig-like_dom | 8.40e-03 | 503 | 47 | 5 | IPR007110 | |
| Pubmed | 2.76e-07 | 39 | 49 | 4 | 1676977 | ||
| Pubmed | Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1. | 7.44e-07 | 13 | 49 | 3 | 34058224 | |
| Pubmed | A mouse carcinoembryonic antigen gene family member is a calcium-dependent cell adhesion molecule. | 7.44e-07 | 13 | 49 | 3 | 1985902 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 15207636 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 19285068 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 21760897 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 1719235 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 10964771 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 32169849 | ||
| Pubmed | CEACAM1+ myeloid cells control angiogenesis in inflammation. | 7.44e-07 | 13 | 49 | 3 | 19273835 | |
| Pubmed | Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. | 7.44e-07 | 13 | 49 | 3 | 16638824 | |
| Pubmed | Mouse hepatitis virus utilizes two carcinoembryonic antigens as alternative receptors. | 7.44e-07 | 13 | 49 | 3 | 1326665 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 20044046 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 32150576 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 21081647 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 11133662 | ||
| Pubmed | Conditional deletion of CEACAM1 in hepatic stellate cells causes their activation. | 7.44e-07 | 13 | 49 | 3 | 39168268 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 22469976 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 11483763 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 6265583 | ||
| Pubmed | CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. | 7.44e-07 | 13 | 49 | 3 | 21532628 | |
| Pubmed | Structural and Molecular Evidence Suggesting Coronavirus-driven Evolution of Mouse Receptor. | 7.44e-07 | 13 | 49 | 3 | 28035001 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 34440862 | ||
| Pubmed | CEACAM1 is a potent regulator of B cell receptor complex-induced activation. | 7.44e-07 | 13 | 49 | 3 | 12832451 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 25406283 | ||
| Pubmed | Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. | 7.44e-07 | 13 | 49 | 3 | 15316023 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 8402684 | ||
| Pubmed | Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. | 7.44e-07 | 13 | 49 | 3 | 21670291 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 22162753 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 2164599 | ||
| Pubmed | In vivo adaptation and persistence of Neisseria meningitidis within the nasopharyngeal mucosa. | 7.44e-07 | 13 | 49 | 3 | 23935487 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 2702644 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 16619040 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 8380065 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 1279194 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 15331748 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 29377208 | ||
| Pubmed | Expression of MHV-A59 receptor glycoproteins in susceptible and resistant strains of mice. | 7.44e-07 | 13 | 49 | 3 | 8209741 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 22673933 | ||
| Pubmed | Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. | 7.44e-07 | 13 | 49 | 3 | 22406619 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 27002145 | ||
| Pubmed | Mice with null mutation of Ceacam I develop nonalcoholic steatohepatitis. | 7.44e-07 | 13 | 49 | 3 | 21949477 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 29396368 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 26219866 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 7628460 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 25724769 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 18003729 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 26284027 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 2133556 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 32521208 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 26374765 | ||
| Pubmed | CEACAM1 specifically suppresses B cell receptor signaling-mediated activation. | 7.44e-07 | 13 | 49 | 3 | 33352461 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 19406938 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 38381498 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 20739537 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 19621080 | ||
| Pubmed | Forced Hepatic Overexpression of CEACAM1 Curtails Diet-Induced Insulin Resistance. | 7.44e-07 | 13 | 49 | 3 | 25972571 | |
| Pubmed | CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection. | 7.44e-07 | 13 | 49 | 3 | 29967450 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 1633107 | ||
| Pubmed | Expression of newly identified secretory CEACAM1(a) isoforms in the intestinal epithelium. | 7.44e-07 | 13 | 49 | 3 | 19358828 | |
| Pubmed | The role of CEA-related cell adhesion molecule-1 (CEACAM1) in vascular homeostasis. | 7.44e-07 | 13 | 49 | 3 | 27695943 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 20404914 | ||
| Pubmed | CEACAM1 deficiency delays important wound healing processes. | 7.44e-07 | 13 | 49 | 3 | 22092845 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 16680193 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 11801635 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 26911181 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 1653760 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 28913658 | ||
| Pubmed | Hepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury. | 7.44e-07 | 13 | 49 | 3 | 32027621 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 19008452 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 18544705 | ||
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 30664851 | ||
| Pubmed | Role for hepatic CEACAM1 in regulating fatty acid metabolism along the adipocyte-hepatocyte axis. | 7.44e-07 | 13 | 49 | 3 | 27777319 | |
| Pubmed | Expression of the mouse hepatitis virus receptor by central nervous system microglia. | 7.44e-07 | 13 | 49 | 3 | 15220458 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 18848945 | ||
| Pubmed | Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. | 7.44e-07 | 13 | 49 | 3 | 8500759 | |
| Pubmed | 7.44e-07 | 13 | 49 | 3 | 18843289 | ||
| Pubmed | Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. | 7.44e-07 | 13 | 49 | 3 | 9343248 | |
| Pubmed | Ceacam1 deletion causes vascular alterations in large vessels. | 7.44e-07 | 13 | 49 | 3 | 23800882 | |
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 37531413 | ||
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 23780386 | ||
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 28567513 | ||
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 8207827 | ||
| Pubmed | CEACAM1 regulates integrin αIIbβ3-mediated functions in platelets. | 9.46e-07 | 14 | 49 | 3 | 26196244 | |
| Pubmed | Human CEACAM1-LF regulates lipid storage in HepG2 cells via fatty acid transporter CD36. | 9.46e-07 | 14 | 49 | 3 | 34666041 | |
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 8896983 | ||
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 19700760 | ||
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 34619794 | ||
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 22962327 | ||
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 17623671 | ||
| Pubmed | Loss of CEACAM1 in endothelial cells causes hepatic fibrosis. | 9.46e-07 | 14 | 49 | 3 | 37088122 | |
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 26846848 | ||
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 14517298 | ||
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 23070997 | ||
| Pubmed | Expression patterns of CD66a and CD117 in the mouse submandibular gland. | 9.46e-07 | 14 | 49 | 3 | 25498293 | |
| Pubmed | Endothelial barrier function is differentially regulated by CEACAM1-mediated signaling. | 9.46e-07 | 14 | 49 | 3 | 29746166 | |
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 9212243 | ||
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 25908210 | ||
| Pubmed | 9.46e-07 | 14 | 49 | 3 | 9047385 | ||
| Pubmed | Ceacam1L Modulates STAT3 Signaling to Control the Proliferation of Glioblastoma-Initiating Cells. | 9.46e-07 | 14 | 49 | 3 | 26238781 | |
| Interaction | PSG3 interactions | 1.77e-05 | 22 | 47 | 3 | int:PSG3 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr19q13 | 2.59e-04 | 1192 | 49 | 7 | chr19q13 | |
| Cytoband | 19q13.2 | 7.31e-04 | 164 | 49 | 3 | 19q13.2 | |
| Cytoband | 7q22.1 | 6.55e-03 | 113 | 49 | 2 | 7q22.1 | |
| GeneFamily | CD molecules|V-set domain containing|Pregnancy specific glycoproteins | 4.86e-07 | 11 | 27 | 3 | 1315 | |
| GeneFamily | Adenosine receptors|V-set domain containing | 9.50e-05 | 163 | 27 | 4 | 590 | |
| GeneFamily | C2-set domain containing|Immunoglobulin like domain containing|Scavenger receptors | 1.62e-03 | 40 | 27 | 2 | 592 | |
| Coexpression | GIBBONS_GENETIC_MOUSE_MODEL_LUNG_ADENOCARCINOMA_DOWN_IN_METASTASIS | 2.93e-05 | 32 | 49 | 3 | MM2 | |
| Coexpression | GSE19401_RETINOIC_ACID_VS_RETINOIC_ACID_AND_PAM2CSK4_STIM_FOLLICULAR_DC_UP | 3.16e-05 | 195 | 49 | 5 | M7680 | |
| Coexpression | OUYANG_PROSTATE_CANCER_MARKERS | 3.85e-05 | 35 | 49 | 3 | MM757 | |
| ToppCell | 3'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 7.36e-07 | 157 | 48 | 5 | c43f2e1ea53b375a7432f17f87cfef3b2261003d | |
| ToppCell | PND07-Endothelial-Endothelial_lymphatic|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 8.34e-07 | 161 | 48 | 5 | 133b4fadb499e842c19f573f9cf09ce08c1d4813 | |
| ToppCell | PND07-Endothelial-Endothelial_lymphatic-Lymphatic_EC|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 8.34e-07 | 161 | 48 | 5 | 9466b8658244116f8d21f2f88fb8c2d184b1bdf2 | |
| ToppCell | PND07-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 8.34e-07 | 161 | 48 | 5 | cb177ca10d848d0e25399ab5ebfcde1071fb94c2 | |
| ToppCell | facs-GAT-Fat-3m-Lymphocytic-CD4-positive,_alpha-beta_T_cell|GAT / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.29e-06 | 176 | 48 | 5 | acd05ca8952710feedbfe377b1330f3c2406d044 | |
| ToppCell | LPS_only-Lymphocytic_NKT-iNKT/MAIT|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.40e-06 | 179 | 48 | 5 | de3ddc1264e43727be50d69b81cc84a3c91812a2 | |
| ToppCell | LPS_only-Lymphocytic_NKT-iNKT/MAIT-iNKT-MAIT|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.40e-06 | 179 | 48 | 5 | def981e97e3ff9019910c9af3861ca0d08eb0d0f | |
| ToppCell | Adult-Immune-natural_killer_cell-D175|Adult / Lineage, Cell type, age group and donor | 1.44e-06 | 180 | 48 | 5 | fc59e28f39e7d4fb1bcc7205202cf39224b70d7b | |
| ToppCell | wk_20-22-Hematologic_Lymphocytic-T_&_ILC-ILC3|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 1.70e-06 | 186 | 48 | 5 | ac1d2a94674bd15885e70502abad3a2ff3c21d73 | |
| ToppCell | wk_15-18-Hematologic_Lymphocytic-T_&_ILC-ILC3|wk_15-18 / Celltypes from embryonic and fetal-stage human lung | 1.74e-06 | 187 | 48 | 5 | a037631a01d2cce088e6522dceeb1eee806522a1 | |
| ToppCell | droplet-Lung-nan-18m-Endothelial-Lymphatic_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.79e-06 | 188 | 48 | 5 | a6ed43fdd42d681c9fbb2fb368947ab7e41d8d7c | |
| ToppCell | droplet-Lung-nan-18m-Endothelial-endothelial_cell_of_lymphatic_vessel|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.79e-06 | 188 | 48 | 5 | 54550313db78b3b5b572fa1e67092c8f6f33aab5 | |
| ToppCell | Adult-Immune-natural_killer_cell|Adult / Lineage, Cell type, age group and donor | 1.93e-06 | 191 | 48 | 5 | 758ec27e47d7662a5175305e98a1506c6859dbf7 | |
| ToppCell | 390C-Lymphocytic-NK_cells|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.30e-06 | 198 | 48 | 5 | 872ddb2738c5e0375830bb0e5b2c50383bf58738 | |
| ToppCell | LPS_only-Hematopoietic_Lymphocytic-Lymphocytic_NK/T-iNKT-MAIT|LPS_only / Treatment groups by lineage, cell group, cell type | 2.36e-06 | 199 | 48 | 5 | b62a756b5472972156d05051a58671a58bef1f16 | |
| ToppCell | Bronchial-10x5prime-Epithelial-Epi_airway_secretory-Secretory_Goblet|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 2.36e-06 | 199 | 48 | 5 | ec1e110671e7725f752163c7241dbbf638dec2b2 | |
| ToppCell | Tracheal-10x3prime_v2-Immune_Lymphocytic-T-T_CD8-CD8_CTL|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 2.36e-06 | 199 | 48 | 5 | 7c63c389c914f1ef2fa92fa153f9ecf1087b8e31 | |
| ToppCell | Parenchymal-NucSeq-Immune_Lymphocytic-NK-ILC-T_NK-NK_CD56bright|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 2.42e-06 | 200 | 48 | 5 | 1db27223e307efca97502fca40ec5e4f8eea512b | |
| ToppCell | droplet-Liver-LIVER_HEPATOCYTES-30m-Myeloid-macrophage/monocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.01e-05 | 149 | 48 | 4 | 48fca6ae33d7722c024b43ce04f4dbce7b6b424b | |
| ToppCell | Control-Lymphocytic_NKT-T_cells-iNKT-MAIT|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.11e-05 | 151 | 48 | 4 | 7e5e35ce601ca3d3722063566e89664909171b8d | |
| ToppCell | droplet-Liver-LIVER_HEPATOCYTES-30m-Myeloid-myeloid_leukocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.17e-05 | 152 | 48 | 4 | 7e686721b95c837f2b0d5116927c8ecacef055ee | |
| ToppCell | 18-Distal-Immune-Immune|Distal / Age, Tissue, Lineage and Cell class | 2.28e-05 | 154 | 48 | 4 | ecfaed6fbffd1305a2216d48ecb33d8a182a9dd9 | |
| ToppCell | droplet-Liver-LIVER_HEPATOCYTES-30m-Lymphocytic-NK_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.79e-05 | 162 | 48 | 4 | 16f9fbcaa0093ffc5a2a5e32db6040e2cb519d47 | |
| ToppCell | PND07-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.79e-05 | 162 | 48 | 4 | 96c6e94a10b124a1d25dcd705ec5aaa8609c1089 | |
| ToppCell | 390C-Lymphocytic-NK_cells-NK_cell_B2|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.85e-05 | 163 | 48 | 4 | 036e65de0f8fc391f3e4d299bf4c05ee5c3b5a37 | |
| ToppCell | PND03-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.99e-05 | 165 | 48 | 4 | 347b59aa625a8a960828b8620824d8ac48990e07 | |
| ToppCell | PND03-Endothelial-Endothelial_lymphatic-Lymphatic_EC|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.99e-05 | 165 | 48 | 4 | 507c89ece0a336b8e9c65b79889a714e17ddca27 | |
| ToppCell | PND03-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.99e-05 | 165 | 48 | 4 | 39a25be081a5d59c7cf107a997d352793d5025fb | |
| ToppCell | PND03-Endothelial-Endothelial_lymphatic|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.99e-05 | 165 | 48 | 4 | 1890f9c33b0c5b381d57f97042da2610a093a6de | |
| ToppCell | PCW_07-8.5-Hematologic_ErythroMegGranulo-Hem_Granulocytic-im_mast/basophil_(18)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 3.06e-05 | 166 | 48 | 4 | f03f78cae6272c89618c0bda032ce45c4fc96baa | |
| ToppCell | PND14-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-VEC|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.29e-05 | 169 | 48 | 4 | 58136b8a0bf2dab45c91a053ef7225ea49ccb871 | |
| ToppCell | facs-Marrow-KLS-24m-Myeloid-promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.29e-05 | 169 | 48 | 4 | d6ad3b637de2935c656aad47ad82d6e8a8bd1227 | |
| ToppCell | PND14-Endothelial-Endothelial_blood-vessel-Macrovascular_EC-VEC-VEC_mature|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.29e-05 | 169 | 48 | 4 | 04c6ed38e1d1befba5ef5f37a3c1e045a0b163d6 | |
| ToppCell | facs-Marrow-KLS-24m-Myeloid-monocyte_+_promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.29e-05 | 169 | 48 | 4 | 60ef186518d0dc63dbded2a77c65cfe3129df754 | |
| ToppCell | PND01-Endothelial-Endothelial_lymphatic-Lymphatic_EC|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.36e-05 | 170 | 48 | 4 | 35e3945d8a540a3e2cec1b559316265aaad023d1 | |
| ToppCell | PND01-Endothelial-Endothelial_lymphatic|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.36e-05 | 170 | 48 | 4 | 0ea625abaa25bab93b70b7000e8f90d5c0f9a0fb | |
| ToppCell | PND01-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.36e-05 | 170 | 48 | 4 | 0b5ddc7d452db0a389927a367914f7d257703f7e | |
| ToppCell | PND14-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.44e-05 | 171 | 48 | 4 | 686f95892c3909973c66c9a27159a070a068f175 | |
| ToppCell | PND14-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.44e-05 | 171 | 48 | 4 | f7ba03e7bdb687f93782c936c7b3374cc5b3b77c | |
| ToppCell | metastatic_Brain-T/NK_cells-Cytotoxic_CD8+_T|metastatic_Brain / Location, Cell class and cell subclass | 3.44e-05 | 171 | 48 | 4 | d3e1cc1b70256c4d01488d6b6130bbcae99bdeec | |
| ToppCell | PND14-Endothelial-Endothelial_lymphatic|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.44e-05 | 171 | 48 | 4 | d0ac50071a3854d02113c455fcc940a6ec59bbb9 | |
| ToppCell | PND14-Endothelial-Endothelial_lymphatic-Lymphatic_EC|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.44e-05 | 171 | 48 | 4 | fbf8e9db00573adcada4b25730e191417b7c9999 | |
| ToppCell | droplet-Spleen-nan-3m-Myeloid-macrophage|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.44e-05 | 171 | 48 | 4 | 5b74df72e36ad04dfb25c72f1ca8efe043f6cda6 | |
| ToppCell | mild_COVID-19-pDC|World / disease group, cell group and cell class (v2) | 3.52e-05 | 172 | 48 | 4 | dab2f1a05c7df58d9387b13271b3f1f1583f9ac3 | |
| ToppCell | 15-Trachea-Immune-Hematopoietic,_Natural_Killer_Cell|Trachea / Age, Tissue, Lineage and Cell class | 3.60e-05 | 173 | 48 | 4 | 6884af1492e8a3bb92a33303d4d5ec3343e88b00 | |
| ToppCell | LPS-IL1RA-Lymphocytic_NKT-iNKT/MAIT-iNKT-MAIT|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.60e-05 | 173 | 48 | 4 | fde1fabb8d13d05998ac3f21ecb1fde6a7a2f337 | |
| ToppCell | LPS-IL1RA-Lymphocytic_NKT-iNKT/MAIT|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.60e-05 | 173 | 48 | 4 | dcde3252ff96448d3a61039a4948c74ad321a218 | |
| ToppCell | 5'-Airway_Nasal-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell-NK_cells|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.68e-05 | 174 | 48 | 4 | 7ebf06076946729c1af25109df6066731097c3b1 | |
| ToppCell | 5'-Airway_Nasal-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell-NK_cells-NK_cells_L.1.3.0.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.68e-05 | 174 | 48 | 4 | 90961e8839514985712b8b986aec3391bb249ba7 | |
| ToppCell | 5'-Airway_Nasal-Immune_Lymphocytic-Lymphocytic_T/NK-natural_killer_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.68e-05 | 174 | 48 | 4 | c4b0987d9394f977fe6bc6a4214a6d8d73d0abcc | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT-iNKT/MAIT|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.68e-05 | 174 | 48 | 4 | 61aa89b56ebda0eba1ba675d5f036992967f670f | |
| ToppCell | mild_COVID-19-pDC|mild_COVID-19 / disease group, cell group and cell class (v2) | 3.76e-05 | 175 | 48 | 4 | b87f279a7519710146c49d6acccb0adedc195965 | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT-iNKT/MAIT-iNKT-MAIT|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.76e-05 | 175 | 48 | 4 | 98cb577df466700e72d1bbc6689205ccf2e7fcba | |
| ToppCell | 5'-GW_trimst-1.5-SmallIntestine-Hematopoietic-T_cells-SELL+_CD4_T|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.94e-05 | 177 | 48 | 4 | 7d73643beb007032e757f2611121c4f3027aecf5 | |
| ToppCell | LPS-IL1RA+antiTNF-Lymphocytic_NKT|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 3.94e-05 | 177 | 48 | 4 | f1efd9c3074d5635700fe7fbebf3dd0b1e0a84f1 | |
| ToppCell | LPS-IL1RA+antiTNF-Lymphocytic_NKT-iNKT/MAIT|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.02e-05 | 178 | 48 | 4 | 7905621f5b2aa55324c5592d1d2fef763a5fa41f | |
| ToppCell | 356C-Lymphocytic-NK_cells-NK_cell_C|356C / Donor, Lineage, Cell class and subclass (all cells) | 4.02e-05 | 178 | 48 | 4 | 7203149864cc8d5ae25329fdbf15c6b73c3d3595 | |
| ToppCell | LPS-IL1RA+antiTNF-Lymphocytic_NKT-iNKT/MAIT-iNKT-MAIT|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.02e-05 | 178 | 48 | 4 | f914092c20130207193f97c6044ae61a9a440a86 | |
| ToppCell | LPS-antiTNF-Lymphocytic_NKT|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.11e-05 | 179 | 48 | 4 | ecea75c568911ff56939c9f67ab901497bd4356c | |
| ToppCell | LPS-IL1RA-Lymphocytic_NKT|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.11e-05 | 179 | 48 | 4 | 5ccf0824611ded5c673d94dff3048aedac12f1a8 | |
| ToppCell | metastatic_Lymph_Node-T/NK_cells-Naive_CD8+_T|metastatic_Lymph_Node / Location, Cell class and cell subclass | 4.20e-05 | 180 | 48 | 4 | 16516dd9c78c27fc76f58d650de9851ffa0763e7 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK-Natural_Killer_Cell_/_Natural_Killer_T_Cell-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.20e-05 | 180 | 48 | 4 | bb2dbf7ed03d5ac765635b7afe738efa822841d0 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_T/NK-Natural_Killer_Cell_/_Natural_Killer_T_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 4.20e-05 | 180 | 48 | 4 | c62417f205bcbf3b212ae177f63562ec6467c855 | |
| ToppCell | metastatic_Brain-T/NK_cells-CD8_low_T|metastatic_Brain / Location, Cell class and cell subclass | 4.20e-05 | 180 | 48 | 4 | 57eced5e314681857a853f7e6bb8b429f157e80e | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.29e-05 | 181 | 48 | 4 | 12ff56fa2949c8d53360cdf2cacfd326e65b54aa | |
| ToppCell | 5'-GW_trimst-1.5-SmallIntestine-Hematopoietic-T_cells-Activated_T|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.29e-05 | 181 | 48 | 4 | dd4126bf3c02e63866e2b3f2db81e3565f0e8c40 | |
| ToppCell | droplet-Limb_Muscle-nan-21m-Macroglial-nan|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.39e-05 | 182 | 48 | 4 | a512863304fad80acaab60a8c6107eb7c9cbac99 | |
| ToppCell | Control-Lymphocytic_NKT-iNKT/MAIT|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.48e-05 | 183 | 48 | 4 | 59e8d07556390828f7557ba3fd2f7d49851498b7 | |
| ToppCell | Control-Lymphocytic_NKT-iNKT/MAIT-iNKT-MAIT|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.48e-05 | 183 | 48 | 4 | 2c5707ada3442eb7100a2a5f9438d5a2ac53a9e1 | |
| ToppCell | BAL-Control-Myeloid-Macrophage-transitional_Macro-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 4.58e-05 | 184 | 48 | 4 | 92202e1cd0bba1ce4b061ebcb8a2af5bb590542a | |
| ToppCell | BAL-Control-Myeloid-Macrophage|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.58e-05 | 184 | 48 | 4 | 7331535d469453a5264dcb0270a97f63d3b55201 | |
| ToppCell | PND07-Immune-Immune_Myeloid-Monocytic-Macrophage-AM|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 4.58e-05 | 184 | 48 | 4 | 8e5fc2bdd3071e782aa8c56b8a39f8ea8f03f623 | |
| ToppCell | 3'-Child09-12-SmallIntestine-Hematopoietic-T_cells-CD8_Tmem|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.58e-05 | 184 | 48 | 4 | 61e2a8b9a42e5788fb4e47c77cc5de65420acbfa | |
| ToppCell | BAL-Control-Myeloid-Macrophage-transitional_Macro|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.58e-05 | 184 | 48 | 4 | 337e38a6b2b6770cc992d88b006829f194841b10 | |
| ToppCell | Control-Lymphocytic_NKT|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.67e-05 | 185 | 48 | 4 | 59d68e119f58b35bab36294758f6b2e25fd8f5c0 | |
| ToppCell | droplet-Lung-nan-21m-Endothelial-endothelial_cell_of_lymphatic_vessel|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.67e-05 | 185 | 48 | 4 | 3a4ae836e882e8d29eb0a2dfab5677f10f2d365f | |
| ToppCell | wk_20-22-Hematologic_Lymphocytic-T_&_ILC-NKT2|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 4.67e-05 | 185 | 48 | 4 | 2d95713deaa05fb3372f4337ef156027e4d8ec8a | |
| ToppCell | droplet-Lung-nan-21m-Endothelial-Lymphatic_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.67e-05 | 185 | 48 | 4 | 224f0b022c21dd40bf1f7503f00b3107ef958975 | |
| ToppCell | droplet-Lung-LUNG-30m-Endothelial-endothelial_cell_of_lymphatic_vessel|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.77e-05 | 186 | 48 | 4 | f23f21781a758541f59c06efa7739d26a03fb478 | |
| ToppCell | droplet-Lung-LUNG-30m-Endothelial-Lymphatic_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.77e-05 | 186 | 48 | 4 | 0de87109da9324c597fadf2eb782f0f158afe832 | |
| ToppCell | PCW_10-12-Immune_Lymphocytic-Immune_Lymphocytic_NK/ILC-im_natural_killer_[NK]_(1)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 4.87e-05 | 187 | 48 | 4 | b5c8322ee728303425be677aa0c36fa552fd0f59 | |
| ToppCell | 390C-Lymphocytic-NK_cells-NK_cell_C|390C / Donor, Lineage, Cell class and subclass (all cells) | 4.87e-05 | 187 | 48 | 4 | 1e8651e6c547384ace5a66b96c6b24a7f390a7ee | |
| ToppCell | droplet-Skin-nan-21m-Lymphocytic-nan|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.87e-05 | 187 | 48 | 4 | 38d7b19fde6811f5fbf548b2464486b197476dc6 | |
| ToppCell | droplet-Skin-nan-21m-Lymphocytic|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.87e-05 | 187 | 48 | 4 | ea33a5bd60b7f5f6d5b07a7f06a5a56395943641 | |
| ToppCell | droplet-Skin-nan-21m-Lymphocytic-T_cell|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.87e-05 | 187 | 48 | 4 | 1dbc2c0ab85033e5de776bbfdb73ebd3a50d2cc6 | |
| ToppCell | droplet-Limb_Muscle-nan-18m-Macroglial-Schwann_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.98e-05 | 188 | 48 | 4 | 8385fd384fc55e3b17802bb6698eb93b2c16d7f2 | |
| ToppCell | LPS_only-Lymphocytic_NKT|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.98e-05 | 188 | 48 | 4 | bbe65b1c11c88ab62d8485cfc3a913ff9da89aad | |
| ToppCell | PCW_10-12-Immune_Lymphocytic-Immune_Lymphocytic_NK/ILC|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 4.98e-05 | 188 | 48 | 4 | 624426815b789f0f35c327b8c3c0c05ba3aa7d98 | |
| ToppCell | droplet-Limb_Muscle-nan-18m-Macroglial|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.98e-05 | 188 | 48 | 4 | cb9d0b48e2fd9cc576132803273b9c0382900944 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_T-CytoT_GZMK+-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 5.08e-05 | 189 | 48 | 4 | f1129eb122bbc051457c5545f1a267beb988b0f2 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_T-CytoT_GZMK+|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 5.08e-05 | 189 | 48 | 4 | 0b012ee301419fa9ccc387c3ff66c2344b349a97 | |
| ToppCell | PCW_13-14-Immune_Lymphocytic-Immune_Lymphocytic_NK/ILC-im_ILC2_(21)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 5.08e-05 | 189 | 48 | 4 | 620d5a71b8cb6288540e2d2d848b9d4d66c1226f | |
| ToppCell | droplet-Lung-18m-Endothelial-lymphatic_endothelial-lymphatic_endothelial_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.18e-05 | 190 | 48 | 4 | e80d66ba0d5c263e94c1ab0b89d1dc7b837af3e1 | |
| ToppCell | PCW_10-12-Immune_Lymphocytic-Immune_Lymphocytic_B-im_lymphoid_progenitor_(7)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 5.18e-05 | 190 | 48 | 4 | bee6a438e217b2abd57aef2a80a9fe14a298d223 | |
| ToppCell | PCW_07-8.5-Immune_Lymphocytic-Immune_Lymphocytic_NK/ILC-im_natural_killer_[NK]_(1)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 5.18e-05 | 190 | 48 | 4 | 5c6801046ab88aad76697984342319872a8f9e38 | |
| ToppCell | droplet-Lung-18m-Endothelial-lymphatic_endothelial-lymphatic_endothelial_cell-lymphatic_endothelial_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.18e-05 | 190 | 48 | 4 | f32d66c0e74e0a2a23ecb857c4daf0d8573a806c | |
| ToppCell | PCW_07-8.5-Immune_Lymphocytic-Immune_Lymphocytic_B-im_lymphoid_progenitor_(7)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 5.18e-05 | 190 | 48 | 4 | 58f2278694931d4b104234810165715b510ab835 | |
| ToppCell | droplet-Lung-18m-Endothelial-lymphatic_endothelial|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.18e-05 | 190 | 48 | 4 | b79ffd05806244a9790cd04c66fb4f92c824e69f | |
| ToppCell | wk_20-22-Hematologic_Lymphocytic-T_&_ILC-NKT1|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 5.18e-05 | 190 | 48 | 4 | 326002d7f9de5e425cee76d9a0277f42d79058e2 | |
| ToppCell | 10x5'v1-week_17-19-Lymphocytic_NK-T_NK-CD56_bright_NK|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 5.18e-05 | 190 | 48 | 4 | 251d50a77e5118a9ad19ea01a7c7c862230ed63c | |
| Computational | Neighborhood of CDKN1C | 6.06e-05 | 27 | 31 | 3 | GNF2_CDKN1C | |
| Computational | Neighborhood of EGFR | 1.02e-04 | 32 | 31 | 3 | GNF2_EGFR | |
| Computational | Neighborhood of IGFBP1 | 1.34e-04 | 35 | 31 | 3 | GNF2_IGFBP1 | |
| Computational | Neighborhood of MMP11 | 2.31e-04 | 42 | 31 | 3 | GNF2_MMP11 | |
| Computational | Neighborhood of TIMP2 | 3.03e-04 | 46 | 31 | 3 | GNF2_TIMP2 | |
| Computational | Neighborhood of KISS1 | 3.66e-04 | 49 | 31 | 3 | GNF2_KISS1 | |
| Disease | pregnancy-specific beta-1-glycoprotein 9 measurement | 1.55e-05 | 4 | 48 | 2 | EFO_0801909 | |
| Disease | pregnancy-specific beta-1-glycoprotein 4 measurement | 3.87e-05 | 6 | 48 | 2 | EFO_0801907 | |
| Disease | Myoinositol measurement | 1.69e-04 | 12 | 48 | 2 | EFO_0021652 | |
| Disease | Hypodontia | 2.33e-04 | 14 | 48 | 2 | C0020608 | |
| Disease | cD177 antigen measurement | 3.90e-04 | 18 | 48 | 2 | EFO_0021866 | |
| Disease | systemic mastocytosis | 7.59e-04 | 25 | 48 | 2 | MONDO_0016586 | |
| Disease | response to aromatase inhibitor | 1.25e-03 | 32 | 48 | 2 | GO_0061477 | |
| Disease | retinal vasculature measurement | 1.49e-03 | 517 | 48 | 5 | EFO_0010554 | |
| Disease | bitter beverage consumption measurement | 2.14e-03 | 42 | 48 | 2 | EFO_0010089 | |
| Disease | cortical surface area measurement | 5.77e-03 | 1345 | 48 | 7 | EFO_0010736 | |
| Disease | alkaline phosphatase measurement | 5.84e-03 | 1015 | 48 | 6 | EFO_0004533 | |
| Disease | total iron binding capacity | 7.19e-03 | 78 | 48 | 2 | EFO_0006334 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| MLSSSEPWGRTPVLP | 366 | Q9H201 | |
| LLGLSSMSIRWPGRP | 6 | Q9UKB5 | |
| WTAPELLRMASPPVR | 701 | P16066 | |
| STIWPTIPIAPDMRG | 1046 | Q9NTI2 | |
| SLSMGPAPRARPWTR | 841 | Q86YV0 | |
| PSTSWMPRRPSCPLK | 81 | Q9H2L5 | |
| LSKRWSPLPPMGTRR | 461 | Q9Y573 | |
| STPWGPAPPLHRRSM | 26 | P55042 | |
| MPVLSRPRPWRGNTL | 1 | P33897 | |
| TMRSITLSWPQPEQP | 446 | P54762 | |
| RRGPEDVSWMSPPLL | 7951 | Q8WXI7 | |
| PSPSPRTPMSWSRIK | 201 | Q5KSL6 | |
| AIPGSVAMPRTWPSS | 181 | P55771 | |
| PPVSARMPTRRWAPG | 36 | P42679 | |
| NPPPLLTWMRDGTVL | 266 | P20916 | |
| RQMEAPGAPPRTLTW | 71 | Q9NPE2 | |
| RPWPCPQENRTSSLM | 51 | Q5VZ46 | |
| TSSLMAPQPPRVWGV | 61 | Q5VZ46 | |
| PSPPRRRGNWITLKM | 1386 | Q3V6T2 | |
| RPGLRTTRMSWPSSF | 76 | P27815 | |
| PNLTSRPTPMTWRLG | 731 | Q8IVL0 | |
| RPTPMTWRLGQACPR | 736 | Q8IVL0 | |
| MASGSRWRPTPPPLL | 1 | Q9P2S2 | |
| PRGPMPLRVDTLTWL | 21 | Q8N7G0 | |
| MTSRTRVTWPSPPRP | 1 | Q86VI4 | |
| MGPLSPARTLRLWGP | 1 | Q96RP7 | |
| RRPLPSPEVMLGQSW | 81 | O15265 | |
| PPWASPQTMQRLSRL | 221 | P11117 | |
| TRSWSPFRSMPPDRL | 1101 | O14559 | |
| CSTMRSKPPPQITWL | 141 | O95727 | |
| PEMWTSAPSLPRLVR | 1621 | Q9BZC7 | |
| PWRFLQTMRLGRSPS | 326 | Q494V2 | |
| MRWFLPDLPPSRSAV | 551 | Q9NS15 | |
| MRGVWPPPVSALLSA | 1 | P42892 | |
| VSTRCLPWRSPMPVS | 431 | Q8IXS0 | |
| MGPLSAPPCTQRITW | 1 | Q00888 | |
| MGPLSAPPCTQRITW | 1 | Q16557 | |
| QESMPILPSWRRGPE | 806 | Q6ZVC0 | |
| RTPSGPPARPSRSMW | 361 | Q2M2I3 | |
| PPARPSRSMWDLSRL | 366 | Q2M2I3 | |
| MGPLPAPSCTQRITW | 1 | Q00887 | |
| MGLPTPQTFRPWSLN | 116 | Q96LK8 | |
| WMLSPFSPPSPARRI | 1171 | Q92954 | |
| SPSNPRDWLNMLSPP | 616 | Q6ZVT6 | |
| LPPSISLWDPSGTIM | 526 | Q14CN2 | |
| SIRSVVFRPPNPWTM | 1246 | A5YKK6 | |
| MISPDPRPSPGLARW | 1 | Q9Y228 | |
| MPRPASESWSPIQSR | 1 | Q8NBB2 | |
| SNMRPQDSWRGPPPL | 861 | Q9H0D6 | |
| RTPPAQLRSPWPMTA | 141 | Q9GZW5 | |
| RRLSWSGIPKPVRPM | 216 | Q8WUA7 | |
| PTWTPRTTRTAPLDM | 161 | Q8N5Q1 |